You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study

 

Online download statistics by month:

Online download statistics by month: March 2020 to July 2025

AbstractFullPdf
Mar 202022222270
Apr 2020215215127
May 202019919957
Jun 20201431438
Jul 2020676717
Aug 2020474718
Sep 202012212225
Oct 2020808023
Nov 2020606113
Dec 2020414113
Jan 2021545434
Feb 2021727220
Mar 202110510531
Apr 2021757512
May 2021424214
Jun 2021343416
Jul 2021404016
Aug 202119198
Sep 2021252516
Oct 2021353528
Nov 2021383826
Dec 2021424223
Jan 2022283017
Feb 2022262814
Mar 2022404115
Apr 2022414621
May 2022868622
Jun 2022535414
Jul 202232339
Aug 2022727317
Sep 2022545512
Oct 2022505411
Nov 2022313315
Dec 2022363612
Jan 2023323212
Feb 2023606014
Mar 202338399
Apr 2023535526
May 2023575816
Jun 2023505116
Jul 2023383817
Aug 2023383810
Sep 2023383810
Oct 2023202011
Nov 2023343411
Dec 202327279
Jan 2024272828
Feb 2024282911
Mar 2024424442
Apr 2024525442
May 2024394018
Jun 2024434221
Jul 2024575833
Aug 2024353516
Sep 2024283015
Oct 2024343427
Nov 2024575814
Dec 2024303113
Jan 2025222614
Feb 2025444437
Mar 2025424221
Apr 2025515119
May 2025353517
Jun 2025262629
Jul 2025110
Total350435451372